| Budget Amount *help |
¥228,540,000 (Direct Cost: ¥175,800,000、Indirect Cost: ¥52,740,000)
Fiscal Year 2021: ¥43,810,000 (Direct Cost: ¥33,700,000、Indirect Cost: ¥10,110,000)
Fiscal Year 2020: ¥43,810,000 (Direct Cost: ¥33,700,000、Indirect Cost: ¥10,110,000)
Fiscal Year 2019: ¥43,810,000 (Direct Cost: ¥33,700,000、Indirect Cost: ¥10,110,000)
Fiscal Year 2018: ¥43,810,000 (Direct Cost: ¥33,700,000、Indirect Cost: ¥10,110,000)
Fiscal Year 2017: ¥53,300,000 (Direct Cost: ¥41,000,000、Indirect Cost: ¥12,300,000)
|
|---|
| Outline of Final Research Achievements |
1) We performed single cell RNA-seq (scRNA-seq) analysis of ovarian cancer tissues and identified a novel stem cell population common to four histologic types of ovarian cancer. 2) We identified genes that regulate serum-induced differentiation of glioblastoma stem cells. 3) scRNA-seq analysis of tumors from tumor-bearing mice treated with a new molecularly targeted drug developed in our laboratory revealed that the immune system in the tumor microenvironment is modulated to suppress tumor growth. Moreover, we have identified and characterized genes involved in the tumorgenicity of glioblastoma and colon cancer cells. We found that 4) the histone deacetylase SIRT2 is critical for the tumorgenicity of glioblastoma stem cells and 5) a novel long non-coding RNA, termed CALIC, plays an important role in colon cancer metastasis.
|
